Aker BioMarine ASA (“Aker BioMarine” or “the company”) reports revenues of USD 75.7 million and Adjusted EBITDA of USD 7.2 million in the fourth quarter 2021. Revenue for the for the full year was USD 262 million with Adjusted EBITDA of USD 48 million and Adjusted EBITDA margin of 18%. This is in line with the company’s guiding.
Aker BioMarine Q4 2021 Report
Aker BioMarine Q4 2021 Slide deck
Aker BioMarine Q4 2021 Webcast recording
“We have ambitious growth plans for our krill business and aim to nearly double revenues over the next four years and lift profitability. In the quarter, we see results of our growth initiatives and report 80% sales growth from the previous quarter for Superba krill oil. We are also pleased with a large increase in sales of Kori, our own consumer brand, as we obtained full distribution at two major US retailers” said Matts Johansen, CEO of Aker BioMarine.
“Research continue to prove the health benefits of krill, and a new and important study shows that krill oil significantly reduces major cardiovascular risk factors. This gives proof that Aker BioMarine is part of the solution to alleviate the burden heart disease has on society”, he concludes.
Highlights:
- Full-year 2021 results in line with company guiding. Revenue of USD 262 million with Adjusted EBITDA of USD 48 million and 18% Adjusted EBITDA margin
- Fourth quarter revenue of USD 75.7 million with Adjusted EBITDA of USD 7.2 million and 9% Adjusted EBITDA margin
- Sales in the Ingredients segment increased 35% from third quarter with strong sales of Superba krill oil
- Sales in the Brands segment increased 22% from third quarter with increased sales in Epion with shipments to Sam’s Club and Costco, both offering Kori nationwide in all stores from early 2022
- Offshore production volumes of 3,101 MT in the quarter and 43,756 MT for the full year
- Continued good performance at the Houston facility with record-high production volumes of krill oil
- Refinancing agreement signed and executed
- Important new study showing that krill oil significantly reduces major cardiovascular risk factors
Aker BioMarine reiterates the guiding for 2022 as presented at the Capital Markets Update in December with expected annual sales growth of between 20-25%, and targeted Adjusted EBITDA margin of 20-25%. The company plans for average annual harvesting volumes of 55,000-60,000 tonnes, although there will be seasonal and operational variations from year to year. The harvesting volume so far in 2022 is 10,750 tonnes.
At 09:00 CET today, the management hosts a webcast. Following a presentation, there will be a Q&A session, where written questions can be submitted to ir@akerbiomarine.com or over a Teams live event.
The webcasted presentation will be in English. To join, please use the link that is available at www.akerbiomarine.com/investor or click here.
A replay of the presentation and Q&A session material will be made available soon after the presentation at the same web address.
For further information, please contact
Carl Christian Bachke, Investor Relations
Mobile: +47 909 808 48
Email: carl.bachke@akerbiomarine.com
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.
About Aker BioMarine
Aker BioMarine is a leading biotech innovator and Antarctic krill-harvesting company developing krill-derived products for pharma, consumer health and wellness as well as animal nutrition. The company has a strong position in its industry and is the world's leading supplier of krill, the natural, powerful and health promoting source of nutrients from the pristine waters of Antarctica. Aker BioMarine is listed on Oslo Stock Exchange (AKBM). More information is available at www.akerbiomarine.com.